Earnings Outlook For Aurinia Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Aurinia Pharmaceuticals (NASDAQ:AUPH) is scheduled to release its quarterly earnings report on February 15, 2024, with analysts expecting an EPS of $-0.16. The company's past earnings performance shows a pattern of beating EPS estimates, which has occasionally led to positive stock price movements the following day. Shares of Aurinia Pharmaceuticals were trading at $7.78 as of February 13, with a 3.35% increase over the last 52 weeks. Investors are likely focused on whether the company will beat the EPS estimate and provide positive guidance for future growth.
February 14, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aurinia Pharmaceuticals is expected to report an EPS of $-0.16 for the upcoming earnings, with a history of beating estimates and positively impacting stock prices post-earnings.
Given Aurinia Pharmaceuticals' history of beating EPS estimates and the positive stock price reactions that followed, there is a high likelihood of a positive short-term impact on AUPH's stock price if the company beats the EPS estimate again and provides optimistic future guidance. The stock's recent performance and the general bullish sentiment among long-term shareholders further support this outlook.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100